The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Szymczak, A. L., Workman, C. J., Wang, Y., Vignali, K. M., Dilioglou, S., Vanin, E. F., & Vignali, D. A. A. (2004) · Nature Biotechnology · doi:10.1038/nbt957 · Cited by 1,059
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Self-citationSavoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.31 · Cited by 377
Kahlon, K. S., Brown, C., Cooper, L. J. N., Raubitschek, A., Forman, S. J., & Jensen, M. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0454 · Cited by 368
Krause, A., Guo, H.-F., Latouche, J.-B., Tan, C., Cheung, N.-K. V., & Sadelain, M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.619 · Cited by 365
Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
Wilkie, S., Picco, G., Foster, J., Davies, D. M., Julien, S., Cooper, L., Arif, S., Mather, S. J., Taylor-Papadimitriou, J., Burchell, J. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4901 · Cited by 346
Self-citationBurchell, J., Durbin, H., & Taylor-Papadimitriou, J. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.1.508 · Cited by 333
Guest, R. D., Hawkins, R. E., Kirillova, N., Cheadle, E. J., Arnold, J., O'Neill, A., Irlam, J., Chester, K. A., Kemshead, J. T., Shaw, D. M., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000161397.96582.59 · Cited by 318
Vera, J., Savoldo, B., Vigouroux, S., Biagi, E., Pule, M., Rossig, C., Wu, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017061 · Cited by 275
Cooper, L. J. N., Topp, M. S., Serrano, L. M., Gonzalez, S., Chang, W.-C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S. J., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1989 · Cited by 248
Gong, M. C., Latouche, J.-B., Krause, A., Heston, W. D. W., Bander, N. H., & Sadelain, M. (1999) · Neoplasia · doi:10.1038/sj.neo.7900018 · Cited by 241
Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.
van de Wiel-van Kemenade, E., Ligtenberg, M. J., de Boer, A. J., Buijs, F., Vos, H. L., Melief, C. J., Hilkens, J., & Figdor, C. G. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.2.767 · Cited by 217
Haynes, N. M., Trapani, J. A., Teng, M. W. L., Jackson, J. T., Cerruti, L., Jane, S. M., Kershaw, M. H., Smyth, M. J., & Darcy, P. K. (2002) · Blood · doi:10.1182/blood-2002-04-1041 · Cited by 197
Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells
Ahmed, N., Ratnayake, M., Savoldo, B., Perlaky, L., Dotti, G., Wels, W. S., Bhattacharjee, M. B., Gilbertson, R. J., Shine, H. D., Weiss, H. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4309 · Cited by 192
Wilkie, S., Burbridge, S. E., Chiapero-Stanke, L., Pereira, A. C. P., Cleary, S., van der Stegen, S. J. C., Spicer, J. F., Davies, D. M., & Maher, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127951 · Cited by 189
Self-citationGallardo, H. F., Tan, C., Ory, D., & Sadelain, M. (1997) · Blood · doi:10.1182/blood.v90.3.952 · Cited by 170
Hombach, A. A., & Abken, H. (2011) · International Journal of Cancer · doi:10.1002/ijc.25960 · Cited by 152
Kofler, D. M., Chmielewski, M. M., Rappl, G., Hombach, A., Riët, T., Schmidt, A., Hombach, A. A., Wendtner, C., & Abken, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.9 · Cited by 141
Álvarez‐Vallina, L., & Hawkins, R. E. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261006 · Cited by 134
Hombach, A. A., Sent, D., Schneider, C., Heuser, C., Koch, D., Pohl, C., Seliger, B., & Abken, H. (2001) · PubMed · Cited by 112
Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: “Are We Nearly There Yet?”
Dotti, G., Savoldo, B., & Brenner, M. K. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.142 · Cited by 98
Weijtens, M. E. M., Hart, E., & Bolhuis, R. L. H. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301051 · Cited by 95
Altenschmidt, U., Kahl, R., Moritz, D. R., Schnierle, B. S., Gerstmayer, B., Wels, W. S., & Groner, B. (1996) · PubMed · Cited by 77
Heslop, H. E. (2010) · Molecular Therapy · doi:10.1038/mt.2010.42 · Cited by 73
Chmielewski, M. M., Hombach, A. A., & Abken, H. (2010) · Gene Therapy · doi:10.1038/gt.2010.127 · Cited by 65
Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy
Jensen, M. C., Cooper, L. J. N., Wu, A. M., Forman, S. J., & Raubitschek, A. A. (2003) · Cytotherapy · doi:10.1080/14653240310001028 · Cited by 61
Immunoediting Sculpts Tumor Epitopes during Immunotherapy
Singh, R., & Paterson, Y. Y. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3960 · Cited by 55
Zhang, Q., Fan, H., Shen, J., Hoffman, R. M., & Xing, H. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009712 · Cited by 53
Hombach, A. A., Heuser, C., Sircar, R., Tillmann, T., Diehl, V., Pohl, C., & Abken, H. (1999) · Journal of Immunotherapy · doi:10.1097/00002371-199911000-00001 · Cited by 52
Combining the Antigen Processing Components TAP and Tapasin Elicits Enhanced Tumor-Free Survival
Lou, Y., Basha, G., Seipp, R. P., Cai, B., Chen, S. S., Moise, A. R., Jeffries, A. P., Gopaul, R., Vitalis, T. Z., & Jefferies, W. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1066 · Cited by 43
Büning, H., Uckert, W., Cichutek, K., Hawkins, R. E., & Abken, H. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.131 · Cited by 36
Retroviral-Mediated Gene Transfer in Primary Murine and Human T-Lymphocytes
Rivière, I., Gallardo, H. F., Hagani, A. B., & Sadelain, M. (2000) · Molecular Biotechnology · doi:10.1385/mb:15:2:133 · Cited by 29
Álvarez‐Vallina, L., & Russell, S. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950018634 · Cited by 25
Jakobsen, M. K., Restifo, N. P., Cohen, P. A., Marincola, F. M., Cheshire, L. B., Linehan, W. M., Rosenberg, S. A., & Alexander, R. B. (1995) · Journal of Immunotherapy · doi:10.1097/00002371-199505000-00004 · Cited by 20
Peinert, S., Kershaw, M. H., & Prince, H. M. (2009) · Immunotherapy · doi:10.2217/imt.09.69 · Cited by 9
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Metadata
- Authors
- Wilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J.
- Venue
- Journal of Clinical Immunology
- Published
- 2012-04-17
- Volume
- 32
- Issue
- 5
- Pages
- 1059-1070
- ISSN
- 0271-9142 (ISSN-L)
- 1573-2592
- OpenAlex
- W1965411082
- Cited by
- 478
- References
- 44
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.